Clinical Intergroup

The European MCL Network consists of 15 national lymphoma study groups supplemented by experts in histopathology and molecular genetics. Selection of individual partners was exclusively based on scientific excellence, profound clinical experience of MCL treatment, broad knowledge of the underlying molecular pathogenesis and outstanding methodological expertise.

 

During the last decade, our European consortium has successfully completed the largest phase III trials in MCL worldwide with a current annual recruitment of almost 200 patients per year in our first line studies. Detailed results have been presented at the last ASH and Lugano conferences.

 
 

 Study Groups

Participating clinical study groups and national representative:

  • Australasian lymphoma study group (J. Seymour, Melbourne/Australia)
  • CLSG (M. Trneny, Prag/Czech Republic)
  • Croatian Study group (I. Aurer, Zagreb/Croatia)
  • FIL (Italian Intergroup) (M. Ladetto, C. Visco, Torino/Italy)
  • GELTAMO (A. Lopez-Guillermo, Barcelona/Spain)
  • GLA (M. Dreyling, Munich/Germany)
  • HOVON (J. Doorduijn, Groningen/Netherlands)
  • Israelian Study group (O. Shpilberg, Petah-Tiqva/Israel)
  • LYSA (O. Hermine, V. Ribrag, St. Le Gouill, Paris/France)
  • NCIC (J. Kuruvilla, Toronto/Canada)
  • NCRI (S. Rule, Plymouth/United Kingdom)
  • Nordic Lymphoma Group (M. Jerkeman, Copenhagen/Denmark)
  • PLRG (J. Walewski, Warzawa/Poland)
  • Portuguese LSG (M. Gomes da Silva, Lisboa/Portugal)
  • SAKK (U. Mey, Chur/Suisse)

 Literature

2020

  • Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH.Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256.
  • Croci GA, Hoster E, Beà S, Clot G, Enjuanes A, Scott DW, Cabeçadas J, Veloza L, Campo E, Clasen-Linde E, Goswami RS, Helgeland L, Pileri S, Rymkiewicz G, Reinke S, Dreyling M, Klapper W. Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. Virchows Arch. 2020 Jan 23. [Epub ahead of print]

 

2019

  • Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly TC, Di Rocco A, Visco C, Carli G, Defrancesco I, Carlo-Stella C, Dreyling M, Santoro A, Arcaini LMantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. Hemasphere. 2019 Dec 16;4(1):e302.
  • Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019 Jun;185(5):940-944
  • Robak T, Smolewski P, Robak P, Dreyling M. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Leuk Lymphoma. 2019 Apr 25:1-13.
  • Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. Br J Haematol. 2019 Feb;184(4):616-624

 

2018

  • Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood. 2018 Dec 27;132(26):2722-2729
  • Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018 Aug;32(8):1799-1803
  • Vidal L, Gafter-Gvili A, Dreyling M, Ghielmini M, Witzens-Harig M, Shpilberg O, Unterhalt M, Rummel M, Gurion R.Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized Trials. Hemasphere. 2018 Jul 27;2(4):e136.
  • Agarwal R, Dawson MA, Dreyling M, Tam CS. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leuk Lymphoma. 2018 Jun 18:1-13
  • Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223.
  • Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M*, Klapper W*. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network. Blood. 2018 Jan 25;131(4):417-420

 

2017

  • Hermine O, Hess G, Jerkeman M, Le Gouill S, Ribrag V, Trněný M, Visco C, Walewski J, Zaja F, Zinzani PL. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leuk Lymphoma. 2017 Nov 27:1-15.
  • Fichtner M, Dreyling M, Binder M, Trepel M. The role of B cell antigen receptors in mantle cell lymphoma. J Hematol Oncol. 2017 Oct 17;10(1):164
  • Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71.
  • Ferrero S, Dreyling M; European Mantle Cell Lymphoma Network Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? Haematologica. 2017 Jul;102(7):1133-1136
  • Hess G, Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M, Bence-Bruckler I, Cho SG, Zhou W, Goldberg JD, Trambitas C, Enny C, Vermeulen J, Traina S, Chiou CF, Diels J, Dreyling M.Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma. 2017 May 30:1-9
  • Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G. B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017 Jan 19;129(3):333-346

 

2016

  • Dreyling M. Combined therapy in MCL: less may be more? Blood. 2016 Oct 6;128(14):1782-1783
  • Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75.
  • Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH*, Klapper W*. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34(12):1386-94
  • Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770-8
  • Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials. Leukemia. 2016;30(6):1428-30
  • Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial. Leukemia. 2016 Apr;30(4):984-7
  • Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, Delfau-Larue MH, Lhermitte L, Thieblemont C, Ribrag V, Cheze S, Sanhes L, Jardin F, Lefrère F, Delarue R, Hoster E, Dreyling M, Asnafi V, Hermine O, Macintyre E. Minimal Residual Disease monitoring by 8-color flow cytometry in Mantle Cell Lymphoma: an EU-MCL and LYSA study. Haematologica. 2016 Mar;101(3):336-45
  • Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica. 2016 Feb;101(2):104-14.

 

2015

  • Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 2015;29:1695-701
  • Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E. CDKN2A and TP53 deletions predict adverse outcome in younger mantle cell lymphoma patients, independent of treatment and MIPI. Blood. 2015 Jul 30;126(5):604-11.
  • Dreyling M. Haematological cancer: Bortezomib in MCL-new standard of care or just another option? Nat Rev Clin Oncol. 2015 Jul;12(7):376-8.
  • Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. Haematologica. 2015 Jun;100(6):706-8.
  • Dreyling M, Amador V, Callanan M, Jerkeman M, Gouill SL, Pott C, Rule S, Zaja F; for the European MCL Network. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma (MCL) - summary of the 12th annual conference of the EUROPEAN MCL NETWORK. Leuk Lymphoma. 2015;56(4):866-76
  • Heinrich DA, Weinkauf M, Hutter G, Zimmermann Y, Jurinovic V, Hiddemann W, Dreyling M. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. Br J Haematol. 2015;168(4):606-10
  • Schreiber S, Hoellein A, Decker T, Jilg S, Dreyling M, Peschel C, Keller U. Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study. Leuk Lymphoma. 2015 Mar 31:1-3
  • Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S, Vitolo U, Dreyling M, Hermine O. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015 Feb;29(2):464-73

 

2014

  • Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F.Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat Med. 2014 Dec;20(12):1401-9.
  • Dreyling M, Ferrero S, Hermine O. How I manage mantle cell lymphoma. Leukemia. 2014 Nov;28(11):2117-30.
  • Dreyling M, Ferrero S, Vogt N, Klapper W; European Mantle Cell Lymphoma Network. New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature? Clin Cancer Res. 2014 Oct 15;20(20):5194-206)
  • Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network. How to treat old MCL patients: one size fits it all? Blood. 2014 Aug 21;124(8):1207-8.
  • Dreyling M; European Mantle Cell Lymphoma Network.Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book. 2014;34:191-8.
  • Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M. Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338-46
  • Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Working Group. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii83-iii92.

 

2013

  • Ferrero S, Dreyling M. The current therapeutic scenario for relapsed mantle cell lymphoma. Curr Opin Oncol. 2013 Sep;25(5):452-62)
  • Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; for the European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013 Aug;24(8):2119-23
  • Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; for the European MCL Network. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma - report of the 11(th) annual conference of the EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Leuk Lymphoma. 2013 Apr;54(4):699-707
  • Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857-77
  • Vazana-Barad L, Granot G, Mor-Tzuntz R, Levi I, Dreyling M, Nathan I, Shpilberg O. Mechanism of the antitumoral activity of Deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymphoma. 2013 Apr;54(4):851-9  

 

2012

  • Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012; 91(11):1765-72
  • Hutter G, Zimmermann Y, Rieken M, Hartmann E, Rosenwald A, Hiddemann W, Dreyling M. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL. Leukemia. 2012; 26(11):2442-4
  • Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31
  • Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W, Dreyling M.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Ann Hematol. 2012;91(6):847-56.

 

2011

  • Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Gouill SL, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2011;52(12):2226-36
  • Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Bredo Pedersen L, Navarro Lopez A, Dagklis A, Rombout P, Beldjord K, Kolstad A, Dreyling MH, Anagnostopoulos A, Tsaftaris A, Mavragani-Tsipidou P, Rosenwald A, Ponzoni M, Groenen P, Ghia P, Sander B, Papadaki T, Campo E, Geisler C, Rosenquist R, Davi F, Pott C, Stamatopoulos K. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011 Sep 15;118(11):3088-95
  • Dreyling M. Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa? Semin Hematol. 2011 Jul;48(3):145-7.
  • Harel S, Delarue R, Ribrag V, Dreyling M, Hermine O. Treatment of younger patients with mantle cell lymphoma. Semin Hematol. 2011 Jul;48(3):194-207.
  • Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2011 Jun 7.
  • Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves over-all survival in elderly patients with mantle cell lymphoma. Blood. 2011;118(18):4808-16.
  • Dreyling M, Polliack A, Tadmor T. Chlorambucil in indolent mantle cell lymphoma - just another old drug for a new disease? Leuk Lymphoma. 2011 Mar;52(3):351-2.
  • Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011 Jan 6;117(1):26-38.

 

2010

  • Dreyling M: Current treatement strategies in mantle cell lymphoma. Hematologicia-Transzfuziologia 2010; 43: 27-28.
  • Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HJ, Hermine O, Macintyre E, Dreyling M. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010, 115: 3215-3223
  • Dreyling M, Hoster E, Bea S, Hartmann E, Horn H, Hutter G, Salaverria I, Pott C, Trneny M, Le Gouill S, Cortelazzo S, Szymczyk M, Jurczak W, Shpilberg O, Ribrag V, Hermine O: Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma. 2010 2010 Sep;51(9):1612-22.
  • Weinkauf M, Hutter G, Zimmermann Y, Hartmann E, Rosenwald A, Dreyling M. Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma. Talanta. 2010 Feb 15;80(4):1539-44. 

 

2009

  • Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma. 2009 Dec;50(12):1937-50.
  • Dreyling M., Hiddemann W.: Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book Hematology 2009: 542-554
  • Hoster E, Dreyling M, Unterhalt M for the German Low-Grade Lymphoma Study Group (GLSG) and the European MCL Network. Response: Statistical power and validation of the MIPI. Blood. 2008 Sep 15; 112(6):2583-2584.
  • Hutter G, Scheubner M, Ott G, Zimmermann Y, Hübler K, Roth S, Stilgenbauer S, Kalla J, Stöcklein H, Hiddemann W, Dreyling M. Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. Ann Hematol. 2009; 88: 821-828.
  • Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma. 2009 May;50(5):716-22.
  • Weinkauf M, Zimmermann Y, Hartmann E, Rosenwald A, Rieken M, Pastore A, Hutter G, Hiddemann W, Dreyling M. 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis. 2009 Mar 23;30(6):974-986.
  • Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009 Feb 1;27(4):511-8.
  • Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd HW, Cabeçadas J, Campo E, Cogliatti S, Hansmann ML, Kluin PM, Kodet R, Krivolapov YA, Loddenkemper C, Stein H, Möller P, Barth TE, Müller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken JH, Wacker HH, Unterhalt M, Hiddemann W, Dreyling M. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009 2(2): 103–111.
  • Deshpande A, Pastore A, Deshpande AJ, Zimmermann Y, Hutter G, Weinkauf M, Buske C, Hiddemann W, Dreyling M. 3'UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle. 2009 Nov 3;8(21): 3584-3592.
  • Vater I, Wagner F, Kreuz M, Berger H, Martín-Subero JI, Pott C, Martinez-Climent JA, Klapper W, Krause K, Dyer MJ, Gesk S, Harder L, Zamo A, Dreyling M, Hasenclever D, Arnold N, Siebert R. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol. 2009 Feb;144(3):317-31

 

2008

  • Weigert O, Dreyling M. Prognosis of mantle cell lymphoma: is it all about proliferation? Leuk Lymphoma. 2008 Nov;49(11):2029-30
  • Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E. Five-gene model to predict survival in mantle-cell lymphoma Using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol. 2008 Oct 20;26(30):4966-72.
  • Dreyling M, Hiddemann W; for the European MCL Network. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Curr Opin Oncol. 2008 Sep;20(5):487-494
  • Stöcklein H, Hutter G, Kalla J, Hartmann E, Zimmermann Y, Katzenberger T, Adam P, Leich E, Höller S, Müller-Hermelink HK, Rosenwald A, Ott G, Dreyling M. Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. J Hematop. 2008 Sep;1(2):85-95
  • Dreyling M, Hiddemann W: Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Current Opinion Oncology 2008, 20: 487-495.
  • Dreyling M, Weigert O, Hiddemann W: Current treatment standards and future strategies in mantle cell lymphoma. Ann Onc 2008, 19 (suppl 4): iv41-44.
  • Nieländer I, Martín-Subero JI, Wagner F, Baudis M, Gesk S, Harder L, Hasenclever D, Klapper W, Kreuz M, Pott C, Martinez-Climent JA, Dreyling M, Arnold N, Siebert R. Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. Haematologica. 2008 Jun; 93(6):949-50.
  • Dreyling M: Hyper-CVAD in mantle-cell lymphoma: Really "hyper" or just hype? Leuk Lymphoma. 2008 Apr 22:1-2.
  • Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol. 2008 Feb;19(2):247-53.
  • Determann O, Hoster E, Ott G, Bernd HW, Loddenkemper C, Hansmann ML, Barth TE, Unterhalt M, Hiddemann W, Dreyling M, Klapper W: Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemo-therapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008 Feb 15;111(4):2385-2387.
  • S Böttcher, M Ritgen, S Buske, Stefan Gesk, W Klapper, E Hoster, W Hiddemann, M Unterhalt, M Dreyling, R Siebert, M Kneba, C Pott on behalf of the EU MCL MRD Group: Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008, Vol 93, Issue 4, 551-559
  • Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008 Jan 15;111(2):558-65.

 

2007

  • Weinkauf M, Christopeit M, Hiddemann W, Dreyling M. Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma. Electrophoresis 2007 Dec;28(23):4416-26.
  • Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs. 2007;67(12):1689-702
  • Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A:Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2;99(9):706-14.
  • Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia. 2007; 21(3):524-528.

 

2006

  • Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Bruggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling M, Hiddemann W, Siebert R, Dreger P, Kneba M. Quantitative assessment of molecular remission following high-dose therapy with autologous stem cell transplantation predicts long term remission in mantle cell lymphoma. Blood 2006,  107: 2271-78
  • Dreyling M, Bergsagel PL, Gordon LI, Cotter FE: Mantle cell lymphoma and other t(11;14) disorders: How biology can drive therapy. ASCO Educational book 2006, 476-484
  • Hutter G, Scheubner M, Zimmermann Y, Kalla J, Katzenberger T, Hubler K, Roth S, Hiddemann W, Ott G, Dreyling M. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. Genes Chromosomes Cancer 45(2):203-10, 2006

 

2005

  • M. Dreyling, G. Lenz, E. Hoster, A. Van Hoof, C. Gisselbrecht, R. Schmits, B. Metzner, L. Truemper, M. Reiser, H. Steinhauer, J. Boiron, M.Boogaerts, A. Aldaoud, V. Silingardi, H. Kluin-Nelemans, J. Hasford, R. Parwaresch, M. Unterhalt and W. Hiddemann: Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous Stem Cell Transplantation in First Remission significantly prolongs Progression-Free Survival in Mantle Cell Lymphoma - Results of a Prospective Randomized Trial of the European MCL Network. Blood 105: 2677-2684, 2005
  • Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, Berger F, Kluin P, Ott G, Pileri S, Pedrinis E, Feller AC, Merz H, Janssen D, Hansmann ML, Krieken H, Moller P, Stein H, Unterhalt M, Hiddemann W, Parwaresch R: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 131(1):29-38, 2005

 

2004

  • G. Lenz, M. Dreyling, W. Hiddemann: Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 83: 71-77, 2004

 

2003

  • Hiddemann W, Dreyling M: Mantle Cell Lymphoma: Therapeutic strategies are different from CLL. Curr Treat Options Oncol 4(3): 219-26, 2003 Lenz G, Dreyling M: Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL? Nat Clin Pract Oncol 2005; 2: 72-73.

 

2002

 

2001

  • L. Sanz-Vaque, D. Colomer, F. Bosch, A. Lopez-Guillermo, M.H. Dreyling, G. Ott, E. Montserrat, E. Campo: Microsatellite instability in typical and progressed mantle cell lymphoma and B-cell-chronic lymphocytic. Haematologica 86: 181-186, 2001

 

2000

 

1999

  • W. Hiddemann, M. Dreyling, M. Tiemann, C. Schrader , M. Unterhalt for the European Mantle Cell Study Group: Mantle cell lymphomas. Haematologica 84: 93-95, 1999
  • Rosenwald, G. Ott, A.K. Krumdiek, M.H. Dreyling, T. Katzenberger, J. Kalla, S. Roth, M.M. Ott, H.K. Müller-Hermelink: A biological role for deletions in chromo-somal band 13q14 in mantle cell and peripheral T-cell lymphomas ? Genes, Chromosomes and Cancer 26: 210-214, 1999
Corporate Partners - Individual Sponsors
Wed, 16th September 2020 to Thu, 17th September 2020
Annual meeting of the European MCL Network
more dates
Tue, 23rd June 2020
The 1st Czernecki Donnelly Prize was awarded to Elisabeth Silkenstedt
more news